Better Pain Management Through Better Data Act of 2018

Bill: 115-hr-5473
Sponsor: full_name: Rep. Comstock, Barbara [R-VA-10]
Introduced: 2018-04-11
Policy area: Health
Subjects: Administrative law and regulatory procedures

Consumer affairs

Department of Health and Human Services

Drug safety, medical device, and laboratory regulation

Drug trafficking and controlled substances

Health information and medical records

Prescription drugs

Public participation and lobbying
Latest action: action_date: 2018-06-13
text: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2018-04-11
action_desc: Introduced in House
text: <p><b>Better Pain Management Through Better Data Act of 2018</b></p> <p>This bill directs the Food and Drug Administration (FDA)to update or issue guidance for drug sponsors on data collection related to the use of other pain medication to reduce the need for opioids. </p> <p>The guidance must address alternative methods for data collection, product labeling, and investigations other than clinical trials.</p>

tv_txt: I 115th CONGRESS 2d Session H. R. 5473 IN THE HOUSE OF REPRESENTATIVES April 11, 2018 Mrs. Comstock (for herself and Mr. Ben Ray Luján of New Mexico ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To direct the Secretary of Health and Human Services to update or issue one or more guidances addressing alternative methods for data collection on opioid sparing and inclusion of such data in product labeling, and for other purposes.

1. Short title This Act may be cited as the Better Pain Management Through Better Data Act of 2018 . 2. Guidance addressing alternative approaches to data collection and labeling claims for opioid sparing (a) In general For purposes of assisting sponsors in collecting and incorporating opioid-sparing data in product labeling, the Secretary of Health and Human Services (referred to in this section as the Secretary ) shall conduct a public meeting and update or issue one or more guidances in accordance with subsection (b). (b) Guidance (1) In general The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall update or issue one or more guidances addressing— (A) alternative methods for data collection on opioid sparing; (B) alternative methods for inclusion of such data in product labeling; and (C) investigations other than clinical trials, including partially controlled studies and objective trials without matched controls such as historically controlled analyses, open-label studies, and meta-analyses, on opioid sparing for inclusion in product labeling. (2) Contents The guidances under paragraph (1) shall address— (A) innovative clinical trial designs for ethically and efficiently collecting data on opioid sparing for inclusion in product labeling; (B) primary and secondary endpoints for the reduction of opioid use while maintaining adequate pain control; (C) use of real world evidence, including patient registries, and patient reported outcomes to support inclusion of opioid-sparing data in product labeling; and (D) how sponsors may obtain feedback from the Secretary relating to such issues prior to— (i) commencement of such data collection; or (ii) the submission of resulting data to the Secretary. (3) Public meeting Prior to updating or issuing the guidances required by paragraph (1), the Secretary shall consult with stakeholders, including representatives of regulated industry, academia, patients, and provider organizations, through a public meeting to be held not later than 12 months after the date of enactment of this Act. (4) Timing The Secretary shall— (A) not later than 12 months after the date of the public meeting required by paragraph (3), update or issue the one or more draft guidances required by paragraph (1); and (B) not later than 12 months after the date on which the public comment period for such draft guidances closes, finalize such guidances. (c) Definition In this section: (1) The terms opioid sparing and opioid-sparing refer to the use of drugs or devices (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 )) that reduce pain while enabling the reduction, replacement, or avoidance of oral opioids. (2) The term Secretary means the Secretary of Health and Human Services.

tv_txt: IIB 115th CONGRESS 2d Session H. R. 5473 IN THE SENATE OF THE UNITED STATES June 13, 2018 Received; read twice and referred to the Committee on Health, Education, Labor, and Pensions AN ACT To direct the Secretary of Health and Human Services to update or issue one or more guidances addressing alternative methods for data collection on opioid sparing and inclusion of such data in product labeling, and for other purposes.

1. Short title This Act may be cited as the Better Pain Management Through Better Data Act of 2018 . 2. Guidance addressing alternative approaches to data collection and labeling claims for opioid sparing (a) In general For purposes of assisting sponsors in collecting and incorporating opioid-sparing data in product labeling, the Secretary of Health and Human Services (referred to in this section as the Secretary ) shall conduct a public meeting and update or issue one or more guidances in accordance with subsection (b). (b) Guidance (1) In general The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall update or issue one or more guidances addressing— (A) alternative methods for data collection on opioid sparing; (B) alternative methods for inclusion of such data in product labeling; and (C) investigations other than clinical trials, including partially controlled studies and objective trials without matched controls such as historically controlled analyses, open-label studies, and meta-analyses, on opioid sparing for inclusion in product labeling. (2) Contents The guidances under paragraph (1) shall address— (A) innovative clinical trial designs for ethically and efficiently collecting data on opioid sparing for inclusion in product labeling; (B) primary and secondary endpoints for the reduction of opioid use while maintaining adequate pain control; (C) use of real world evidence, including patient registries, and patient reported outcomes to support inclusion of opioid-sparing data in product labeling; and (D) how sponsors may obtain feedback from the Secretary relating to such issues prior to— (i) commencement of such data collection; or (ii) the submission of resulting data to the Secretary. (3) Public meeting Prior to updating or issuing the guidances required by paragraph (1), the Secretary shall consult with stakeholders, including representatives of regulated industry, academia, patients, and provider organizations, through a public meeting to be held not later than 12 months after the date of enactment of this Act. (4) Timing The Secretary shall— (A) not later than 12 months after the date of the public meeting required by paragraph (3), update or issue the one or more draft guidances required by paragraph (1); and (B) not later than 12 months after the date on which the public comment period for such draft guidances closes, finalize such guidances. (c) Definition In this section: (1) The terms opioid sparing and opioid-sparing refer to the use of drugs or devices (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 )) that reduce pain while enabling the reduction, replacement, or avoidance of oral opioids. (2) The term Secretary means the Secretary of Health and Human Services.

Passed the House of Representatives June 12, 2018. Karen L. Haas, Clerk

tv_txt: I 115th CONGRESS 2d Session H. R. 5473 IN THE HOUSE OF REPRESENTATIVES AN ACT To direct the Secretary of Health and Human Services to update or issue one or more guidances addressing alternative methods for data collection on opioid sparing and inclusion of such data in product labeling, and for other purposes.

1. Short title This Act may be cited as the Better Pain Management Through Better Data Act of 2018 . 2. Guidance addressing alternative approaches to data collection and labeling claims for opioid sparing (a) In general For purposes of assisting sponsors in collecting and incorporating opioid-sparing data in product labeling, the Secretary of Health and Human Services (referred to in this section as the Secretary ) shall conduct a public meeting and update or issue one or more guidances in accordance with subsection (b). (b) Guidance (1) In general The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall update or issue one or more guidances addressing— (A) alternative methods for data collection on opioid sparing; (B) alternative methods for inclusion of such data in product labeling; and (C) investigations other than clinical trials, including partially controlled studies and objective trials without matched controls such as historically controlled analyses, open-label studies, and meta-analyses, on opioid sparing for inclusion in product labeling. (2) Contents The guidances under paragraph (1) shall address— (A) innovative clinical trial designs for ethically and efficiently collecting data on opioid sparing for inclusion in product labeling; (B) primary and secondary endpoints for the reduction of opioid use while maintaining adequate pain control; (C) use of real world evidence, including patient registries, and patient reported outcomes to support inclusion of opioid-sparing data in product labeling; and (D) how sponsors may obtain feedback from the Secretary relating to such issues prior to— (i) commencement of such data collection; or (ii) the submission of resulting data to the Secretary. (3) Public meeting Prior to updating or issuing the guidances required by paragraph (1), the Secretary shall consult with stakeholders, including representatives of regulated industry, academia, patients, and provider organizations, through a public meeting to be held not later than 12 months after the date of enactment of this Act. (4) Timing The Secretary shall— (A) not later than 12 months after the date of the public meeting required by paragraph (3), update or issue the one or more draft guidances required by paragraph (1); and (B) not later than 12 months after the date on which the public comment period for such draft guidances closes, finalize such guidances. (c) Definition In this section: (1) The terms opioid sparing and opioid-sparing refer to the use of drugs or devices (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 )) that reduce pain while enabling the reduction, replacement, or avoidance of oral opioids. (2) The term Secretary means the Secretary of Health and Human Services.

Passed the House of Representatives June 12, 2018. Karen L. Haas, Clerk.